Molecular Diagnostics
July 9 - 10, 2018 - London UKSMi Group
ssapal@smi-online.co.uk
Phone:02078276000
The global molecular diagnostics market is forecasted to reach over US$10 billion in the next three years, at a CAGR of 9.1% from 2016 to 2021*. In an ever-evolving universe of molecular diagnostics, it is vital to keep up with emerging and developing technology, products and applications. Furthermore, companies must comply to the constantly change regulatory environment and tackle the challenging process if implementing these regulations. SMi welcomes you to explore the expanding market opportunities, the latest diagnostics advancements and regulatory requirements at the 5th Molecular Diagnostics Conference. This event is CPD accredited. CHAIR: Hugues Malonne, Director General, DG Post Autorisation, Federal Agency for Medicines And Health Products, Belgium KEY THEMES FOR MOLECULAR DIAGNOSTICS 2018: - Regulatory changes, challenges and outlook - Advances in laboratory technologies, including: biochips, nanotechnologies and proteomic technologies - Personalised medicine And pharmacogenomics - Diagnostic methods at the point of care - Molecular Diagnostics in Prenatal, Infectious Disease and Cancer (*The Market Report can be found here: https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html.) WHO SHOULD ATTEND Attendees will primarily be drawn from the following backgrounds/departments: Molecular Diagnostic, Cancer Immunology, Immunobiology, Biomarkers, Radiation Oncology, Therapeutic Radiology, Translational Medicine, Translational Assays Technologies, Companion Diagnostics, Clinical Chemistry, Experimental Medicine and Diagnostics. They will include Leads, Directors, Heads, Project Managers, Principal Investigators, Principal Scientists, Senior Scientists, Research Scientist, Professors, Researchers and Clinical Analysts, amongst others.